A Phase 2 interventional study of GZR4 Injection and Insulin Degludec in Diabetes Mellitus, Type 2, sponsored by Gan and Lee Pharmaceuticals, USA. Completed at 8 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-01-23.
Sponsored by Gan and Lee Pharmaceuticals, USA · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Diabetes Mellitus, Type 2 by Gan & Lee Pharmaceuticals — 6 open to participants now, 9 under way, 1 of them phase 3. Diabetes Mellitus, Type 2 · Gan & Lee Pharmaceuticals.
Among the 17 studies in Diabetes Mellitus, Type 2 by Gan & Lee Pharmaceuticals, this one is the 7th largest by enrollment, is one of 3 that started in 2023, is one of 6 in phase 2, and was the 4th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →6 of the 17 studies in Diabetes Mellitus, Type 2 by Gan & Lee Pharmaceuticals are open now, in 2 countries. Recruiting first, the newest first:
Gan & Lee Pharmaceuticals. · Sites in China
Ages 18+
Gan and Lee Pharmaceuticals, USA · Sites in Germany
Ages 18–70
Gan and Lee Pharmaceuticals, USA · Sites in China
Ages 18–75
Gan & Lee Pharmaceuticals. · Sites in China
Ages 18–75
Gan & Lee Pharmaceuticals. · Sites in China
Ages 18–60
By country, each count listing its studies:
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 7 · Phase 3 4
First in 2017; this study’s year is marked. 3 started in 2023.
This study's enrollment of 179 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 92 across the 17 interventional studies. Of the 8 that completed or were terminated, 1 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Gan and Lee Pharmaceuticals, USA, one of the names counted as Gan & Lee Pharmaceuticals. Under that name alone:
Gan and Lee Pharmaceuticals, USA is the lead sponsor of 29 studies on the registry; 5 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 2 (25%) have results posted.
1 of the studies in Diabetes Mellitus, Type 2 by Gan & Lee Pharmaceuticals that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07387003Gan & Lee Pharmaceuticals.Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes | 2027-02-11 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies in Diabetes Mellitus, Type 2 by Gan & Lee Pharmaceuticals, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study compares the efficacy, safety, and tolerability of once-weekly GZR4 Injection versus once-daily insulin degludec in patients with type 2 diabetes mellitus in inadquete control on oral antidiabetic drug (OAD) therapy or OAD Therapy in combination with basal insulin.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GZR4 Injection + Oral Antidiabetic Drug
Drug: GZR4 Injection
Insulin Degludec + Oral Antidiabetic Drug
Drug: Insulin Degludec
GZR4 injection s.c., once-weekly, treat-to-target dose
Insulin Degludec s.c., once-daily, treat-to-target dose
Change in HbA1c
Change from baseline in HbA1c after 16 weeks of treatment
Time frame: From baseline (week 0) to week 16
Change in fasting plasma glucose(FPG)
Change from baseline in fasting plasma glucose (FPG) after 16 weeks of treatment
Time frame: From baseline (week 0) to week 16
Weekly doses of GZR4 Injection/Insulin Degludec
Weekly doses of once-weekly GZR4 Injection and once-daily Insulin Degludec Injection from week 15 to week 16 are presented.
Time frame: Week 15-16
Incidence and Rate of Treatment-emergent adverse events (TEAEs)
A TEAE is defined as an event that had onset date (or increase in severity) during the on-treatment observation period.
Time frame: From baseline (week 0) to week 20
Incidence and Rate of hypoglycemia episodes
Hypoglycaemia alert episodes (level 1) are defined as episodes that are sufficiently low for treatment with fast-acting carbohydrate and dose adjustment of glucose-lowering therapy with plasma glucose value of equal to or above (\>=) 3.0 and less than (\<) 3.9 mmol/L (\>= 54 and \< 70 mg/dL) confirmed by blood glucose (BG) meter. Clinically significant hypoglycaemic episodes (level 2) are defined as episodes that are sufficiently low to indicate serious, clinically important hypoglycaemia with plasma glucose value of less than (\<) 3.0 mmol/L (54 mg/dL). Severe hypoglycaemic episodes (level 3) are defined as episodes that were associated with severe cognitive impairment requiring external assistance for recovery. Severe hypoglycaemic episodes (level 3) are defined as episodes that are associated with severe cognitive impairment requiring external assistance for recovery.
Time frame: From baseline (week 0) to week 20
Change in ADA of GZR4
Blood samples will be analysed for anti-GZR4 antibodies
Time frame: From baseline (week 0) to week 16
Change in Nab of GZR4
Blood samples will be analysed for Nab
Time frame: From baseline (week 0) to week 16
Plan to share: No
No publications or documents are linked to this record.
Ran from Aug 2023 to primary completion in Jul 2024, 11 months.
Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 11 months is below that.
Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Gan and Lee Pharmaceuticals, USA →